How more people can find your latest article | Promote your research
Want your research to reach more people? Make the most of your connections! Here’s how to do it in 4 easy ways.
Want your research to reach more people? Make the most of your connections! Here’s how to do it in 4 easy ways.
Paolo Tarantino: HER2 is about to change again / AstraZeneca, Breast Cancer, cancer, Cancer Discovery, DESTINY-Breast06 Trial, Enhertu, HER2-low Breast
PHILADELPHIA (May 6, 2024) — In a study presented today at the American Urological Association (AUA) Annual Meeting 2024, researchers from Fox Chase Cancer Center…
Yi-Bin Chen, MD, proposes a strategy to enhance patients’ quality of life by utilizing virtual monitoring as an alternative to requiring patients to travel to…
The American Cancer Society aims to enroll over 100,000 Black, cancer-free women between the ages of 25 and 55 and follow them for three decades.
In a retrospective cohort study (SPOTLIGHT), investigators found that a substantial proportion of patients with unresectable stage III NSCLC did not receive consolidation durvalumab after…
Longtime Fred Hutchinson Cancer Center supporters Carl and Renee Behnke have committed $15M to help launch an ambitious new comprehensive campaign. In recognition, the South…
Summary. Combination immune-checkpoint inhibition with chemotherapy is a clinical standard, yet concurrent administration may limit the full benefit of immunotherapy by blunting the proliferation and…
Patients with CLL/SLL who received second-line venetoclax experienced monthly cost savings compared with those who received a second-line BTK inhibitor.
Miriam Merad was named dean for Translational Research and Therapeutic Innovation of the Icahn School of Medicine at Mount Sinai. To access this subscriber-only content…
Sima Porten, MD, MPH, discusses the rationale for the phase 3 SunRISe-5 study of TAR-200 in non-muscle invasive bladder cancer and unmet needs in this…